Back to Search
Start Over
Enhancing the Efficacy of HIPEC Through Bromelain: A Preclinical Investigation in Appendiceal Cancer.
- Source :
-
Annals of surgical oncology [Ann Surg Oncol] 2024 Aug; Vol. 31 (8), pp. 5377-5389. Date of Electronic Publication: 2024 May 04. - Publication Year :
- 2024
-
Abstract
- Introduction: Appendiceal cancer (AC) excessive mucin production is a barrier to heated intraperitoneal chemotherapy (HIPEC) drug delivery. Bromelain is a pineapple stem extract with mucolytic properties. We explored bromelain treatment effects against mucinous AC in a patient-derived tumor organoid (PTO) model and an AC cell line.<br />Patients and Methods: PTOs were fabricated from tumor specimens obtained from patients with AC undergoing cytoreductive surgery with HIPEC. PTOs underwent HIPEC treatment with bromelain, cisplatin, and mitomycin C (MMC) at 37 °C and 42 °C with and without bromelain pretreatment.<br />Results: From October 2020 to May 2023, 16 specimens were collected from 13 patients with low-grade (12/16, 75%) and high-grade AC (4/16, 25%). The mucin-depleting effects of bromelain were most significant in combination with N-acetylcysteine (NAC) compared with bromelain (47% versus 10%, p = 0.0009) or NAC alone (47% versus 12.8%, p = 0.0027). Bromelain demonstrated > 31% organoid viability reduction at 60 min (p < 0.001) and > 66% in 48 h (p < 0.0001). Pretreatment with bromelain increased cytotoxicity of both cisplatin and MMC HIPEC conditions by 31.6% (p = 0.0001) and 35.5% (p = 0.0001), respectively. Ki67, CK20, and MUC2 expression decreased after bromelain treatment; while increased caspase 3/7 activity and decreased Bcl-2 (p = 0.009) and Bcl-xL (p = 0.01) suggest induction of apoptosis pathways. Furthermore, autophagy proteins LC3A/B I (p < 0.03) and II (p < 0.031) were increased; while ATG7 (p < 0.01), ATG 12 (p < 0.04), and Becline 1(p < 0.03), expression decreased in bromelain-treated PTOs.<br />Conclusions: Bromelain demonstrates cytotoxicity and mucolytic activity against appendiceal cancer organoids. As a pretreatment agent, it potentiates the cytotoxicity of multiple HIPEC regimens, potentially mediated through programmed cell death and autophagy.<br /> (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Subjects :
- Humans
Male
Female
Middle Aged
Apoptosis drug effects
Antineoplastic Combined Chemotherapy Protocols pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Tumor Cells, Cultured
Mitomycin pharmacology
Mitomycin administration & dosage
Aged
Cell Proliferation drug effects
Cytoreduction Surgical Procedures
Adenocarcinoma, Mucinous pathology
Adenocarcinoma, Mucinous therapy
Adenocarcinoma, Mucinous drug therapy
Adenocarcinoma, Mucinous metabolism
Prognosis
Follow-Up Studies
Bromelains pharmacology
Appendiceal Neoplasms pathology
Appendiceal Neoplasms therapy
Appendiceal Neoplasms drug therapy
Hyperthermic Intraperitoneal Chemotherapy
Cisplatin pharmacology
Cisplatin administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1534-4681
- Volume :
- 31
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Annals of surgical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38704503
- Full Text :
- https://doi.org/10.1245/s10434-024-15355-0